Control Bionics (ASX: CBL) has entered into an agreement with Tobii Dynavox to evaluate a distribution partnership for its NeuroNode® technology in the United States. The six-month pilot programme covers five northwestern states and positions the medical device company to access established distribution channels through a global leader in Augmentative and Alternative Communication (AAC) solutions.
The Control Bionics Tobii Dynavox partnership replaces a previous Tobii Dynavox partner in the US market. NeuroNode is designed to complement Tobii Dynavox’s existing AAC portfolio by providing eye gaze users with an alternative access method. This collaboration validates Control Bionics’ surface electromyography (sEMG) technology within a sector where Tobii Dynavox holds a leading market position.
Tobii Dynavox is widely recognised as a global leader in AAC solutions, with a long history of delivering access and communication technology to individuals with communication disabilities. Control Bionics brings more than 20 years of experience in sEMG device development, enabling individuals to control technology through minimal muscle activation where traditional access methods may not be viable.
What is Augmentative and Alternative Communication technology?
Augmentative and Alternative Communication (AAC) technology helps individuals with communication disabilities express themselves through digital solutions. These systems range from simple picture-based communication boards to sophisticated computer-based devices that generate speech and enable text communication.
Eye gaze technology allows users to control a cursor by tracking eye movement, functioning like a computer mouse. However, eye gaze systems typically require an additional method to perform the “click” function. This is where Control Bionics’ NeuroNode technology provides a complementary solution.
NeuroNode is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle, captured as electromyography (EMG) output. This output is sent wirelessly to a personal computer, enabling speech and other computer-controlled functions like email and texting. Control Bionics’ technology integrates three modalities: touch, eye gaze, and NeuroNode control. Combined, these yield unique benefits in terms of patient expression speed and reduced fatigue.
The addressable market for AAC solutions continues to expand as technology improves access for individuals with conditions such as motor neurone disease, cerebral palsy, and stroke-related communication impairments. Control Bionics’ 20+ years of sEMG expertise creates product differentiation in a sector where patient-specific customisation drives adoption.
Join thousands of readers who start here
Our best articles, sent straight to your inbox. You can unsubscribe anytime.
Pilot structure and US market opportunity
The evaluation agreement positions NeuroNode within Tobii Dynavox’s established sales channels, offering a strategic market entry approach that reduces the capital requirements of a direct sales model. The pilot period provides both companies with an opportunity to assess commercial viability before committing to broader distribution arrangements.
| Element | Detail |
|---|---|
| Partner | Tobii Dynavox |
| Duration | Six months |
| Geography | Five northwestern US states |
| Product | NeuroNode technology |
Three key structural elements underpin the partnership:
- NeuroNode replaces a previous Tobii Dynavox partner in the US, indicating the global AAC leader actively sought an alternative sEMG solution.
- The technology complements existing eye gaze solutions rather than competing with Tobii Dynavox’s core products.
- NeuroNode provides an alternative access method where traditional options may not be viable, expanding the addressable patient population.
The US represents the largest addressable market for AAC solutions, with established reimbursement pathways and a mature healthcare infrastructure. Partnering with Tobii Dynavox provides Control Bionics with access to existing commercial relationships rather than requiring ground-up market development.
CEO commentary on strategic rationale
Chief Executive Officer Jeremy Steele positioned the agreement as a validation of Control Bionics’ technology and a potential pathway to broader US market access. The pilot structure allows both companies to evaluate commercial fit before committing to expanded distribution.
“Tobii Dynavox is a global leader in AAC, and we are pleased to be partnering with them to introduce NeuroNode into selected regions of the U.S. market. We believe this collaboration has the potential to meaningfully enhance how people access and use communication technology. While this is an initial six-month pilot, we see real potential in the partnership, and we look forward to exploring the opportunity for a broader U.S. expansion over time.”
Management’s commentary suggests the company views this as a strategic entry point rather than a standalone arrangement. If the pilot demonstrates commercial traction, the partnership could extend to additional states and provide a scalable distribution model for the US market.
Enjoyed this article?
We publish high-impact stories like this a few times a week. No spam.
What success looks like for Control Bionics investors
The six-month evaluation period provides a defined timeline for investors to assess partnership viability. Success would likely manifest as conversion to a broader distribution agreement covering additional US states, potentially accelerating revenue generation without proportional increases in sales and marketing expenditure.
Control Bionics currently operates across multiple geographies, including North America, Australia, Singapore, and Japan. The Tobii Dynavox partnership could significantly expand US market penetration through established channels rather than requiring direct sales infrastructure build-out.
Key milestones for investors to monitor include:
- Pilot completion and conversion to a broader distribution agreement
- Geographic expansion beyond the initial five northwestern states
- Feedback from Tobii Dynavox sales channels on product-market fit and customer adoption
The company is also commercialising NeuroStrip, a miniaturised EMG device targeting markets such as health diagnostics, sports performance, and rehabilitation. This diversification strategy provides additional growth avenues beyond the AAC sector.
The Control Bionics Tobii Dynavox partnership represents a validation opportunity with material upside if the pilot succeeds. Investors should monitor the six-month timeline for indicators of commercial traction, including any announcements regarding expanded geographic coverage or formal distribution agreements beyond the pilot phase.
Want more Biotech breakthroughs delivered to your inbox?
Control Bionics’ partnership with Tobii Dynavox demonstrates how established medical device companies are validating emerging sEMG technologies in the AAC sector. This type of strategic collaboration—where distribution channels accelerate market access without proportional capital investment—is exactly the kind of development that moves biotech and healthcare stocks.
Investors tracking ASX-listed biotech companies can access breaking news and detailed analysis through StockWire X, which delivers FREE Big News Blasts to over 20,000+ active subscribers. These alerts cover non-resource sectors including biotech, healthcare, technology, and financials—providing the context needed to assess commercial milestones like pilot conversions, partnership expansions, and regulatory approvals. Click the “Free Alerts” button in the menu to receive comprehensive market intelligence as these stories develop.